
Swedish biotech firm Strike Pharma has secured financial backing to further advance its antibody-based technology for the development of individualized immunotherapeutic treatments for cancer and to bring its first candidate to clinic.
This comes after the Uppsala-based company has succeeded in closing a SEK 45m (USD 4.8m) financing round, which was led by Danish-Swedish venture capital fund Eir Ventures and also saw participation from Swedish Flerie Invest.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app